News
Focusing on Markets with Unmet Needs
Insmed is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases and protein-based therapeutics.
Learn more about us
February 10, 2012 - Insmed announced that the Company is proceeding with a phase 2 clinical trial of ARIKACE®(liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria (NTM) lung disease, as well as the previously planned European registration phase 3 clinical study of ARIKACE in Cystic Fibrosis (CF) patients with Pseudomonas aeruginosa (Pa) lung infections. Insmed will continue its discussions with the U.S. Food and Drug Administration (FDA) regarding the clinical hold previously placed on the ARIKACE U.S. clinical study in CF patients with (Pa) lung infections.
For more information, please see the press release dated February 10, 2012 in our newsroom.
For more information, please see the press release dated February 10, 2012 in our newsroom.